Cancer-associated venous thrombosis in the surgical setting.
OBJECTIVE
Cancer patients are at a relatively high risk of venous thromboembolism (VTE), and this has implications for surgical outcome.


METHODS
English literature search including the keywords cancer, surgery and VTE was undertaken to review the risk, etiology, prevention and treatment of VTE in surgical oncology patients.


RESULTS
Malignant disease is highlighted as an important risk factor for VTE with an odds ratio of 6.5. The risk factors include higher age, previous VTE, advanced cancer, length of operation and immobility.


CONCLUSIONS
Use of in-hospital thromboprophylaxis with low-molecular-weight heparin (LMWH) or low dose unfractionated heparin with graded stockings has been validated both in terms of safety and efficacy and should be considered for all patients. Subcutaneous LMWH has replaced unfractionated heparin for the initial treatment of VTE. The use of long-term LMWH instead of oral anticoagulants can substantially reduce the risk of recurrent VTE without increased bleeding. Recently, results of few trials have shown that LMWH may improve patient survival.
Behranwala
Kasim A
KA
Department of Surgery, Hammersmith Hospital, London, UK. kbehranwala@hotmail.com
Williamson
Robin C N
RC
D000925:Anticoagulants / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008403:Mass Screening; D009369:Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000601:surgery*; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D054556:Venous Thromboembolism / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D020246:Venous Thrombosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight